Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder

Borhan, Walaa; Cimino‐Mathews, Ashley; Montgomery, Elizabeth A.; Epstein, Jonathan I.

doi:10.1097/pas.0000000000000922

Cited by 33 publications

(44 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Half of reported cases also showed conventional urothelial carcinoma or urothelial carcinoma in situ. [76][77][78][79][80][81] The urothelial nature of the proliferating cells can be confirmed by immunostains for the urothelial lineage markers CK7, CK20, p63, GATA3 and uroplakin III. CD138 (plasma cells marker) is positive in onethird of cases.…”

Section: Plasmacytoid/signet Ring Cell/diffuse Urothelial Carcinomamentioning

confidence: 91%

“…Extreme discohesive growth patterns mimicking infiltrating lobular carcinoma of the breast and diffuse carcinoma of the stomach have been described. Half of reported cases also showed conventional urothelial carcinoma or urothelial carcinoma in situ …”

Section: Plasmacytoid/signet Ring Cell/diffuse Urothelial Carcinomamentioning

confidence: 99%

“…The patients typically present at an advanced stage with a high relapse and mortality rate, and with frequent peritoneal carcinomatosis. Plasmacytoid carcinoma appears to be chemotherapy responsive …”

Section: Plasmacytoid/signet Ring Cell/diffuse Urothelial Carcinomamentioning

confidence: 99%

“…The plasmacytoid carcinoma variant of urothelial carcinoma is rare and aggressive, and is characterised by the presence of discohesive individual cells that resemble plasma cells ( Figure 6). [76][77][78][79][80][81] In addition to the plasmacytoid morphology, a number of single cells with cytoplasmic vacuoles, with or without mucin, which impart a signet ring cell appearance, are typically present ( Figure 6). 1 These tumours are not associated with any extracellular mucin production, a useful parameter to differentiate plasmacytoid carcinoma from adenocarcinoma with signet ring cells, which is associated with extracellular mucin.…”

Section: Plasmacytoid/signet Ring Cell/diffuse Urothelial Carcinomamentioning

confidence: 99%

“…Plasmacytoid carcinoma appears to be chemotherapy responsive. [76][77][78][79][80][81] Loss of E-cadherin, encoded by the CDH1gene, has been described recently in a large cohort of patients with plasmacytoid urothelial carcinoma and may account for the marked discohesion of these malignant cells. Loss of E-cadherin protein by immunohistochemistry may be seen in approximately 70% of plasmacytoid carcinomas, in contrast to only 11% of conventional urothelial carcinomas.…”

Section: Plasmacytoid/signet Ring Cell/diffuse Urothelial Carcinomamentioning

confidence: 99%

See 4 more Smart Citations

Variants and new entities of bladder cancer

et al. 2018

View full text Add to dashboard Cite

Pathological evaluation of bladder cancer typically reveals great tumour heterogeneity, and therefore the common observation of urothelial carcinoma exhibiting a wide variety of histopathological patterns is not surprising. Some of these patterns are so distinctive that they have been recognised as specific variants of urothelial carcinoma. Classifications have recently been revised in the 2016 World Health Organisation (WHO) classification of tumours of the urinary system and male genital organs. The current WHO classifications clarify terminological issues and provide better definition criteria, but also incorporate some new entities. Many of these variants have important prognostic or therapeutic implications worth knowing by the urologist and oncologist, but also represent diagnostic challenges in daily pathology practice. This review will discuss the features of variants of urothelial carcinoma in the context of our current clinical practice. Histological variations and new entities of bladder cancer not included in the current WHO classification of urothelial tumours will be briefly discussed.

show abstract

Section: Plasmacytoid/signet Ring Cell/diffuse Urothelial Carcinomamentioning

confidence: 91%

Section: Plasmacytoid/signet Ring Cell/diffuse Urothelial Carcinomamentioning

confidence: 99%

Section: Plasmacytoid/signet Ring Cell/diffuse Urothelial Carcinomamentioning

confidence: 99%

Section: Plasmacytoid/signet Ring Cell/diffuse Urothelial Carcinomamentioning

confidence: 99%

Section: Plasmacytoid/signet Ring Cell/diffuse Urothelial Carcinomamentioning

confidence: 99%

See 3 more Smart Citations

Variants and new entities of bladder cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma

et al. 2021

View full text Add to dashboard Cite

Objectives The aim of this study is to assess the course and management of poorly differentiated bladder urothelial carcinoma (UC), including plasmacytoid UC (PUC), in our local area. Although bladder cancer is relatively common, PUC is a rare and aggressive subtype with a poor prognosis that is still poorly understood. Materials and Methods A retrospective assessment of all poorly differentiated high‐grade UC over the last 15 years (2005–2020) in the Hunter New England area was completed. In total, 37 patients were included, and PUC variant was compared with the remaining poorly differentiated UC. Results Of the included cases, eight were PUC, nine squamous variant, two neuroendocrine, and one sarcomatoid. Overall, 23 cases proceeded to cystectomy, 15 had chemotherapy (six neoadjuvant), and 11 had radiation therapy. In the PUC subgroup, three had metastatic disease at diagnosis (37.5%). Of the three PUC patients who underwent cystectomy, all were upstaged. Two PUC cases had adjuvant chemotherapy, and one case had radiation. Within the follow‐up period, the PUC group had a cause‐specific mortality of 50% with a mean survival in these patients of 202 days, compared with 37.9% cause‐specific mortality with survival of 671.55 days (p = 0.23) in all other undifferentiated UC cases; 5‐year cause‐specific mortality with Kaplan–Meier analysis was estimated at 26% compared with 59%, respectively (p = 0.058). Conclusion Poorly differentiated UC is demonstrated to have a poor prognosis with a high mortality rate, particularly when PUC is present. Given the rarity of these variants, further studies are necessary to explore the impact of current treatment options.

show abstract

Lobular Breast Lesions

Troxell

Chen

et al. 2019

Practical Breast Pathology

View full text Add to dashboard Cite

Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder

Cited by 33 publications

References 28 publications

Variants and new entities of bladder cancer

Variants and new entities of bladder cancer

Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma

Lobular Breast Lesions

Contact Info

Product

Resources

About